Literature DB >> 21131268

Effect of methamphetamine self-administration on neurotensin systems of the basal ganglia.

Paul S Frankel1, Amanda J Hoonakker, Mario E Alburges, Jacob W McDougall, Lisa M McFadden, Annette E Fleckenstein, Glen R Hanson.   

Abstract

Methamphetamine (METH) dependence causes alarming personal and social damage. Even though many of the problems associated with abuse of METH are related to its profound actions on dopamine (DA) basal ganglia systems, there currently are no approved medications to treat METH addiction. For this reason, we and others have examined the METH-induced responses of neurotensin (NT) systems in the basal ganglia. This neuropeptide is associated with inhibitory feedback pathways to nigrostriatal DA projections, and NT tissue levels are elevated in response to high doses of noncontingent METH because of its increased synthesis in the striatonigral pathway. The present study reports the contingent responses of NT in the basal ganglia to self-administration of METH (SAM). Intravenous infusions of METH linked to appropriate lever-pressing behavior by rats significantly elevated NT content in both dorsal striatum (210%) and substantia nigra (202%). In these same structures, NT levels were also elevated in yoked METH animals (160 and 146%, respectively) but not as much as in the SAM rats. These effects were blocked by a D1, but not D2, antagonist. A NT agonist administered before the day 5 of operant behavior blocked lever-pressing behavior in responding rats, but a NT antagonist had no significant effect on this behavior. These are the first reports that NT systems associated with striatonigral pathway are significantly altered during METH self-administration, and our findings suggest that activation of NT receptors during maintenance of operant responding reduces the associated lever-pressing behavior.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21131268      PMCID: PMC3061538          DOI: 10.1124/jpet.110.176610

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  32 in total

Review 1.  The nucleus accumbens as part of a basal ganglia action selection circuit.

Authors:  Saleem M Nicola
Journal:  Psychopharmacology (Berl)       Date:  2006-09-16       Impact factor: 4.530

2.  Brain levels of neuropeptides in human chronic methamphetamine users.

Authors:  Paul S Frankel; Mario E Alburges; Lloyd Bush; Glen R Hanson; Stephen J Kish
Journal:  Neuropharmacology       Date:  2007-06-28       Impact factor: 5.250

3.  D2R striatopallidal neurons inhibit both locomotor and drug reward processes.

Authors:  Pierre F Durieux; Bertrand Bearzatto; Stefania Guiducci; Thorsten Buch; Ari Waisman; Michele Zoli; Serge N Schiffmann; Alban de Kerchove d'Exaerde
Journal:  Nat Neurosci       Date:  2009-03-08       Impact factor: 24.884

4.  Hyperactivity of the dopaminergic system in NTS1 and NTS2 null mice.

Authors:  Yanqi Liang; Mona Boules; Zhimin Li; Katrina Williams; Tomofumi Miura; Alfredo Oliveros; Elliott Richelson
Journal:  Neuropharmacology       Date:  2010-03-06       Impact factor: 5.250

5.  The reversal of amphetamine-induced locomotor activation by a selective neurotensin-1 receptor agonist does not exhibit tolerance.

Authors:  David Feifel; Gilia Melendez; Rachel J Murray; Dan N Tina Tran; Michelle A Rullan; Paul D Shilling
Journal:  Psychopharmacology (Berl)       Date:  2008-06-21       Impact factor: 4.530

6.  Differential response of neurotensin to methamphetamine self-administration.

Authors:  Paul S Frankel; Amanda J Hoonakker; Glen R Hanson
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

7.  Effects of chronic infusion of neurotensin and a neurotensin NT1 selective analogue PD149163 on amphetamine-induced hyperlocomotion.

Authors:  C Norman; S R G Beckett; C H Spicer; D Ashton; X Langlois; G W Bennett
Journal:  J Psychopharmacol       Date:  2008-01-21       Impact factor: 4.153

8.  Differential effects of methamphetamine and SCH23390 on the expression of members of IEG families of transcription factors in the rat striatum.

Authors:  Genevieve Beauvais; Subramaniam Jayanthi; Michael T McCoy; Bruce Ladenheim; Jean Lud Cadet
Journal:  Brain Res       Date:  2010-01-06       Impact factor: 3.252

Review 9.  Pharmacotherapy of methamphetamine addiction: an update.

Authors:  Ahmed Elkashef; Frank Vocci; Glen Hanson; Jason White; Wendy Wickes; Jari Tiihonen
Journal:  Subst Abus       Date:  2008       Impact factor: 3.716

10.  Effect of a novel neurotensin analog, NT69L, on nicotine-induced alterations in monoamine levels in rat brain.

Authors:  Yanqi Liang; Mona Boules; Amanda M Shaw; Katrina Williams; Paul Fredrickson; Elliott Richelson
Journal:  Brain Res       Date:  2008-07-19       Impact factor: 3.252

View more
  27 in total

1.  Prior methamphetamine self-administration attenuates serotonergic deficits induced by subsequent high-dose methamphetamine administrations.

Authors:  Lisa M McFadden; Madison M Hunt; Paula L Vieira-Brock; Janice Muehle; Shannon M Nielsen; Scott C Allen; Glen R Hanson; Annette E Fleckenstein
Journal:  Drug Alcohol Depend       Date:  2012-05-28       Impact factor: 4.492

2.  Prior nicotine self-administration attenuates subsequent dopaminergic deficits of methamphetamine in rats: role of nicotinic acetylcholine receptors.

Authors:  Michelle G Baladi; Shannon M Nielsen; J Michael McIntosh; Glen R Hanson; Annette E Fleckenstein
Journal:  Behav Pharmacol       Date:  2016-08       Impact factor: 2.293

3.  Mephedrone alters basal ganglia and limbic dynorphin systems.

Authors:  Christopher L German; Mario E Alburges; Amanda J Hoonakker; Annette E Fleckenstein; Glen R Hanson
Journal:  Synapse       Date:  2014-09-08       Impact factor: 2.562

4.  Prior methamphetamine self-administration attenuates the dopaminergic deficits caused by a subsequent methamphetamine exposure.

Authors:  Lisa M McFadden; Paula L Vieira-Brock; Glen R Hanson; Annette E Fleckenstein
Journal:  Neuropharmacology       Date:  2015-01-31       Impact factor: 5.250

5.  Diverse actions of the modulatory peptide neurotensin on central synaptic transmission.

Authors:  Christopher W Tschumi; Michael J Beckstead
Journal:  Eur J Neurosci       Date:  2018-02-28       Impact factor: 3.386

6.  Neurotensin speeds inhibition of dopamine neurons through temporal modulation of GABAA and GABAB receptor-mediated synaptic input.

Authors:  Christopher W Tschumi; Michael J Beckstead
Journal:  Neuropharmacology       Date:  2018-01-05       Impact factor: 5.250

7.  Alterations in the striatal dopamine system during intravenous methamphetamine exposure: effects of contingent and noncontingent administration.

Authors:  Goran Laćan; Martin Hadamitzky; Ronald Kuczenski; William P Melega
Journal:  Synapse       Date:  2013-03-19       Impact factor: 2.562

8.  Response of limbic neurotensin systems to methamphetamine self-administration.

Authors:  G R Hanson; A J Hoonakker; M E Alburges; L M McFadden; C M Robson; P S Frankel
Journal:  Neuroscience       Date:  2012-01-02       Impact factor: 3.590

9.  Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure.

Authors:  Lisa M McFadden; Greg C Hadlock; Scott C Allen; Paula L Vieira-Brock; Kristen A Stout; Jonathan D Ellis; Amanda J Hoonakker; David M Andrenyak; Shannon M Nielsen; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2011-10-27       Impact factor: 4.030

10.  Responses of the rat basal ganglia neurotensin systems to low doses of methamphetamine.

Authors:  Mario E Alburges; Amanda J Hoonakker; Nathaniel M Cordova; Christina M Robson; Lisa M McFadden; Amber L Martin; Glen R Hanson
Journal:  Psychopharmacology (Berl)       Date:  2014-02-13       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.